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COMPARISON OF DALLY (5 MG/DAY AND 15 MG/DAY) 
ORAL DOSING REGIMENS OF RISEDRONATE TO HEALTHY 
MALE AND FEMALE VOLUNTEERS. D.E. B u r g i o , ~  L. A. 
Sun, MD, PhD, D. A. Russell, BS, D. J. Whitham, BS, R. Eusebio, 
MS, G. A. Thompson, PhD, P&GP, Mason, OH. 
Purpose. To compare the pharmacokinefics of risedronate admin- 
istered as multiple daily oral doses of 5 and 15 mg in healthy male 
and female volunteers. Methods,  This was a 20 week (2 groups; 
24-28 subjects per group, age range 43-75 yr), multiple-dose, ran- 
domized, parallel group design study. Serum samples were obtained 
on Days 1, 85, and 112-115. Urine samples were obtained on Days 1, 
8, 29, 57, 78, 85, 105, 112-140. Risedronate concentrations were 
determined by ELISA. Serum and urine data were simultaneously 
analyzed using nonlinear regression. 
Results. Results are given as LS/Geometric Mean. 
Ratio/Diff 
Parameter 5 mg/day 15 mg/day (95 % Conf. Interval) 
Dose-norm C ..... 0.303 0.290 0.958 (0.766,1.199) 
(ng/mL/mg) 
Dose-norm Cavg 0.068 0.061 0.892 (0.710,1.120) 
(ng/mL/mg) 
Dose-norm Cram 0.030 0.029 0.950 (0.677,1.333) 
(ng/mL/mg) 
Dose-norm AUCta u 1.665 1.467 0.882 (0.706,1.100) 
(ng*lgmL/mg) 
A' e (%) (/.432 0.364 0.843 (0.660,1.077) 
tma x (h) 0.736 0.667 -0.069 (-0.210,0.072) 
CL, (L/h/kg) 8.06 9.25 1.149 (0.909,1.452) 
CLR (L/h/kg) 0.035 0.034 0.969 (0.810,1.159) 
t~/2. z (h) 420 377 0.899 (0.657,1.231) 
Conclusions, Analysis of predicted Cm~ n indicated that risedronate 
pharmacokinetics achieved steady-state by Day 57. As indicated by 
the pharmacokinetic parameters, the steady-state pharmacokinetics 
were shown to be dose proportional between 5 and 15 mg/day. Both 
risedronate dosing regimens were well tolerated by the study popu- 
lation. 
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PHARMACOKINETICS OF CAPECITABINE GIVEN IN COM- 
BINATION WITH OXALIPLAT1N: A PILOT STUDY OF ADULT 
CANCER PATIENTS. X. Guo, MD, PhD, A. Ernst, J. Grem, MD, 
NCI/NIH, Bethesda, MD. 
Capecitabine (cape), an oral pro-drug of 5-ftuorouracil (5FU), & 
oxaliplatin are both active chemotherapeutic agents in the treatment 
of adult advanced colorectal cancer. The aims of this study are to 
determine the pharmacokinetic (PK) profile of cape & its metabolites, 
& to define any possible PK interaction between the drugs. Patients 
received a single dose of cape to permit PK sampling. The next week, 
oxaliplatin 130mg/m2 IV/2 hr was given on day 1, followed by cape 
twice daily on days 2-5 & 8-12. After 9-day rest, cape was given 
twice daily starting after the oxaliplatin on days 1-5 & 8-12 every 3 
weeks in cycle 2. Blood samples were taken from 14 patients, 6 at 
1650mg and 8 at 2300mg half-daily dose, were subjected to PK 
analysis by non-compartmental methods. Plasma levels of cape & its 
nucleoside metabolites were measured by high-performance liquid 
chromatography-mass spectroscopy; 5-FU & fluoro-beta alanine 
were measured by gas chromatography-mass spectroscopy. Cape is 
rapidly absorbed from gastrointestinal tract with Tmax of 1.5 hour for 
both dosing groups. The elimination half-life is 0.62 hr (0.3-1.5 hr). 
For cape, the Cmax is 7.4 mg/L & 11.68 mg/L (1650 & 2300 mg); the 
AUC (0-t) is 9.2 & 10.03 mg*hr/L (1650 & 2300 mg). For 5-FU, the 
Tmax is 1.9 hr & 1.6 hr for 1600 & 2300 mg; the terminal half-life 
is 0.60 hr for both groups of patients; the Cmax is 0.14 & 0.23 ug/L 
for 1650 & 2300 mg; the AUC(0-t) was calculated as 0.22 & 0.845 
mg*hr/L (1650 & 2300 mg). 
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PLASMA CONCENTRATIONS OF DESETHYLOXYBUTY- 
NIN (DEO), THE PRIMARY ACTIVE METABOLITE OF OXY- 
BUTYNIN (OXY), ARE INVERSELY RELATED TO SALIVARY 
PRODUCTION. D. R. Guav, P h a r ~  University of Minnesota, 
Minneapolis, MN. 
Purpose. Oral OXY is subject to presystemic metabolism, result- 
ing in high plasma levels of the active metabolite DEO. Oral OXY 
extended-release (OXY-ER) attempts to reduce the peak-trough ex- 
cursions in plasma concentrations of OXY and reduce plasma DEO. 
This study compared the phannacokinetics (PK) of a new OXY 
transdermal delivery system (OXY-TDS) with OXY-ER and corre- 
lated PK parameters with salivary gland output. 
Methods. In a randomized, open-label, 2-way crossover trial, 
healthy subjects were assigned to either two OXY-TDS applications 
(3.9 mg/d for 7.5 days) or OXY-ER (10 mg/d for 6 days), then the 
alternate treatment after a 5-7 day washout. Blood was collected 
serially over the last 96 hours of drug administration and analyzed for 
OXY and DEO content. Saliva weight was measured at regular 
intervals by chewing Parafilm ® for 2 minutes and determining the 
weight of the expectorant minus the premeasured weight of the film. 
Results. Significantly more saliva production (P = 0.0167) oc- 
curred during OXY-TDS compared with OXY-ER treatment. There 
was also a significant inverse correlation (r = -0.5865; P = 0.0351) 
between plasma DEO concentration and saliva production. 
Conclusions. These results demonstrate a significant association 
between increased plasma DEO concentrations and decreased saliva 
output in healthy volunteers. Clinically, OXY-TDS therapy would be 
expected to produce a lower incidence of dry mouth due to the 
reduced DEO concentrations associated with its use. 
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PHYSICOCHEMICAL FACTORS ON THE HYDROLYSIS OF 
DIPYRONE. H. Ergun, MD, M. Aravind, BSc, D. A. Frattarelli, 
MD, J. V. Aranda, MD, PhD, Wayne State Uni. Children's Hospital 
of Michigan, Wayne State University, Children's Hospital of Mich- 
igan, Detroit, MI. 
Dipyrone is a prodrug, which is used mainly for its analgesic and 
antipyretic effects. Several other beneficial effects (vascular smooth 
muscle relaxant, antiapoptotic, and anticonvulsant) have been re- 
ported. After oral intake, dipyrone is rapidly hydrolyzed to its main 
metabolite 4-methylaminoantipyrine (4-MAA). The active metabo- 
Iite(s) of dipyrone are not well known. It has been found that only 
4-MAA and 4-AA saliva concentrations correlate with the analgesic 
effect of dipyrone. However in most of the studies in which dipyrone 
is used, the prodrug form is tested using in vitro methodologies, 
which do not represent or predict the actual in vivo activity of 
dipyrone. In this study we have characterized the hydrolysis kinetics 
of dipyrone as a function of pH, concentration, and temperature. 
Dipyrone and 4-MAA were measured by HPLC. 
Acid-catalyzed hydrolysis is the major reaction at lower concen- 
tration (10uM) of dipyrone. At higher concentrations ( lmM) other 
factor(s) are involved in the reaction. Ionic strength is an important 
factor in the hydrolysis. Low concentrations of dipyrone are hydro- 
lyzed more rapidly than concentrated solutions. Temperature cata- 
lyzes the hydrolysis reaction, significantly. These physicochemical 
factors must be considered in in vitro and in vivo studies, as well as 
in designing clinical trials of dipyrone. 
